Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Approves Novartis-Alcon Merger with Conditions -- Update

publication date: Aug 17, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China’s Ministry of Commerce approved the merger between Swiss biopharma Novartis and eye-products company Alcon, though it did require CIBA VISION, a division of Novartis, to terminate its Sales and Distribution Agreement with HaiChang, one of the largest contact lens sellers in China, within the next 12 months. The MoC said Novartis-Alcon together enjoy a 55% stake in the affected markets worldwide and a 60% share in China. More details...

Stock Symbols: (NYSE: NVS) (NYSE: ALC)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners